As of June 14, 2025, BB Biotech AG (BION.SW) reports a Net Margin of 67.62%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of BB Biotech AG's Net Margin
Over recent years, BB Biotech AG's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 67.62% |
| 2023-12-31 | -38982.45% |
| 2022-12-31 | -28375.26% |
| 2021-12-31 | 117.82% |
| 2020-12-31 | 93.18% |
This slight upward trend highlights how BB Biotech AG manages its overall profitability and cost control over time.
Comparing BB Biotech AG's Net Margin to Peers
To better understand BB Biotech AG's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| BB Biotech AG (BION.SW) | 67.62% |
| Impax Environmental Markets PLC (IEM.L) | 537.10% |
| Rolinco NV (ROLA.AS) | 509.95% |
| Fidelity China Special Situations PLC (FCSS.L) | 123.25% |
| Blackrock World Mining Trust PLC (BRWM.L) | 123.23% |
| JPMorgan American Investment Trust PLC (JAM.L) | 97.55% |
Compared to its competitors, BB Biotech AG's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.